Rallybio is a clinical-stage biotechnology company with a mission to discover, develop, manufacture, and deliver therapies that improve the lives of patients with severe and rare diseases. Built around a team of seasoned industry leaders, Rallybio is determined to overcome science's toughest obstacles and transform the treatment landscape. They are committed to developing transformative therapies by following the science wherever it leads.

Rallybio's unique advantage lies in their decades of experience in drug discovery, research, development, regulatory strategy, and manufacturing. Additionally, they have a vast network of relationships with academic clinical centers and industry leaders worldwide. By leveraging their team's expertise and working in parallel paths, Rallybio aims to make unparalleled progress in developing and implementing novel clinical trial designs.

With a diversified portfolio of product candidates, Rallybio strives to significantly improve the lives of patients suffering from devastating and rare diseases